ArticleInterdisciplinary cardiovascular and thoracic surgery2025
Impact of Initial Axillary Microaxial Flow Pump on Post-Myocardial Infarction Ventricular Septal Defect Management.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe mortality rate of ventricular septal defect (VSD) following acute myocardial infarction remains high. Mechanical circulatory support devices have been shown to facilitate delayed surgery and improve postoperative survival, although clear guidelines for device selection are lacking.
methodsThis study presents a retrospective cohort analysis of 18 patients with post-infarction VSD treated with microaxial flow pump (mAFP) from March 2017 to November 2024. Patients were divided into 2 groups: the percutaneous group utilized Impella 2.5 or CP (Abiomed, Danvers, MA, USA) and the axillary access group (Impella 5.0 or 5.5). Their clinical outcomes and early to midterm survival rates were analysed.
resultsThe survival discharge rate was 31% (4 in 13 patients) in the percutaneous group and 100% (5 patients) in the axillary access group, with a significant difference (P = .029). Seven patients who were initially managed with percutaneous mAFP and later required the addition of extracorporeal membrane oxygenation all died perioperatively. The 100-day Kaplan-Meier analysis showed a significant improvement in survival rates in the axillary access group compared to the percutaneous group (log-rank, P = .020).
conclusionsThese findings illustrate variation in surgical timing and device selection and suggest that the early use of an axillary access mAFP may warrant further investigation in post-myocardial infarction VSD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.